Notably, two BACE1 inhibitors, which underwent clinical trials for AD, also cross inhibited BACE2’s ability to cleave VEGFR3, and the effect was reflected by plasma levels of sVEGFR3 in patients with AD who were treated with those inhibitors (18). Here, BACE1 is linked to Alzheimer disease.